Athera Biotechnologies AB Company Details: Series unknown Funding Signal

Athera Biotechnologies AB Overview

Headquarters: Stockholm, Stockholms Län, Se
Phone Number: Available in AeroLeads
Website: athera.se
Industry: Biotechnology Research
Employees: 1
Funding: 5.9M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Immunovascular disease Clinical stage development Fully human monoclonal antibodies Therapeutic antibodies oxidised phospolipids cardiovascular disease vascular inflammation

About Athera Biotechnologies AB

Athera was a clinical stage biopharmaceutical company focused on developing targeted anti-inflammatory biological candidate drugs for the prevention and treatment of immunovascular disease. The Company initiated its lead program in 2005, based on innovations made at Karolinska Institutet, Sweden. The development of the antibody therapy was in part co-financed by the EU FP7 program, in the project CARDIMMUN. Athera closed down operations in 2021, after reporting of a clinical Phase 2 study.